OpenBiome hosted a webinar with physicians from Boston Children’s Hospital, Texas Children’s Hospital, and the University of Minnesota about managing pediatric Clostridioides difficile infection, including diagnostic considerations and investigational fecal microbiota transplantation (FMT).
The Q&A features Peggy Lillis Foundation CEO and co-founder Christian John Lillis, who works to build a nationwide C. diff awareness movement through public education, advocacy, and policy work. He is Peggy Lillis’s eldest son; Peggy died at 56 from C. diff.
Eric is a Professor of Biological Engineering at MIT and an Associate Member of the Broad Institute. His research spans topics from biofuels to human disease, and he works to translate human microbiome research into therapies that improve patients’ liv
Jane is a powerhouse in the life sciences sector. A 2024 PharmaVoice 100 honoree and Vice President of of Neuroscience and Rare Disease at Syneos Health, she leads a global team of medical directors, guiding biotech firms through the complexities of clinical drug development and asset strategy.
OpenBiome Foundation describes the potential of microbiome-targeted therapies to change outcomes for people with serious conditions, including Clostridioides difficile infection.
OpenBiome Foundation says it provided investigational fecal microbiota transplantation (FMT) therapy to thousands of patients with Clostridioides difficile before regulatory changes forced it to stop delivering the treatments.
